home / stock / mnpr / mnpr news

MNPR News and Press, Monopar Therapeutics Inc. From 06/14/23

Stock Information
Company Name: Monopar Therapeutics Inc.
Stock Symbol: MNPR
Market: NASDAQ
Website: monopartx.com
Menu
MNPR MNPR Quote MNPR Short MNPR News MNPR Articles MNPR Message Board
Get MNPR Alerts

News, Short Squeeze, Breakout and More Instantly...
MNPR - Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will partic...
MNPR - Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

Patient in 520 mg/m 2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m 2 cohort achieved stable disease WILMETTE, Ill., June 01, 2023 (...

MNPR - Marker, Nano-X top healthcare gainers, Belite, Phio among losers

2023-05-31 10:05:20 ET Gainers: Marker Therapeutics ( MRKR ) +34% . Nano-X Imaging ( NNOX ) +13% . Zai Lab ( ZLAB ) +9% . Invivyd ( IVVD ) +8% . Corbus Pharmaceuticals ( CRBP ) +7% . Losers: Belite Bio ( BLTE ) ...

MNPR - Monopar Therapeutics GAAP EPS of -$0.19 beats by $0.03

2023-05-11 10:03:26 ET Monopar Therapeutics press release ( NASDAQ: MNPR ): Q1 GAAP EPS of -$0.19 beats by $0.03 . Cash, cash equivalents and short­term investments as of March 31, 2023, were $11.7 million. For further details see: Monopar Therapeutics G...
MNPR - Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

WILMETTE, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical­stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today anno...

MNPR - THMO, CNET and LOOP among mid-day movers

2023-03-28 13:10:56 ET Gainers: Biomea Fusion ( BMEA ) +73% . Oscar Health ( OSCR ) +72% . Viking Therapeutics ( VKTX ) +63% . Pyxis Oncology ( PYXS ) +46% . Bird Global ( BRDS ) +44% . NaaS Technology ( NAAS ) +26% ....

MNPR - Biomea, Oscar top healthcare gainers; Monopar, OncoSec lead losers' pack

2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...
MNPR - iHeartMedia, Invesco Mortgage Capital, FiscalNote among premarket losers' pack

2023-03-28 08:31:04 ET Monopar Therapeutics MNPR -50% as Validive program gets axed after trial failure . WiSA Technologies WISA -28% after proposes securities offering . OncoSec Medical ( ONCS ) -25% . Allarity Therapeutics ALLR -18% amid enr...

MNPR - Monopar to Present at the Jefferies Radiopharma Innovation Summit

WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson...

MNPR - Monopar stock crashes ~50% as Validive program gets axed after trial failure

2023-03-28 05:57:36 ET Monopar Therapeutics' ( NASDAQ: MNPR ) is discontinuing the active development of Validive after the drug did not meet the required efficacy to prevent severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) in a phase 2b/3 trial ca...
Previous 10 Next 10